Zelira Therapeutics(ZLDAF)
$0.200.00 (0.00%)
ZLDAF
Zelira Therapeutics financials statements
$0.20
At close:0.00 (0.00%)
Zelira Therapeutics (ZLDAF) Ratios
16 Followers
Zelira Therapeutics Ratios
ZLDAF's free cash flow for Q4 2025 was AU$-2.27M. For the 2025 fiscal year, ZLDAF's free cash flow was increased by AU$0.00 and operating cash flow was AU$-2.27M. See a summary of the company’s cash flow.
| Ratios | Jun 25 | Jun 24 | Jun 23 | Jun 22 | Jun 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.11 | 0.60 | 0.94 | 3.12 | 5.66 |
| Quick Ratio | 0.02 | 0.42 | 0.13 | 1.92 | 4.86 |
| Cash Ratio | 0.00 | 0.08 | 0.08 | 1.69 | 4.62 |
| Solvency Ratio | -0.60 | -3.86 | -2.31 | -5.65 | -5.26 |
| Operating Cash Flow Ratio | -0.88 | -0.62 | -3.85 | -5.80 | -8.01 |
| Short-Term Operating Cash Flow Coverage | -2.47 | -1.24 | -50.86 | -80.78 | -95.18 |
| Net Current Asset Value | AU$ -4.98M | AU$ -5.10M | AU$ -407.97K | AU$ 3.07M | AU$ 4.55M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.65 | 1.15 | 0.01 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | -0.48 | -1.32 | 0.01 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | -0.92 | 4.15 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | -0.88 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.29 | -1.15 | 1.07 | 1.07 | 1.04 |
| Debt Service Coverage Ratio | -1.21 | -8.30 | -25.76 | -69.02 | -60.32 |
| Interest Coverage Ratio | -9.71 | -8.03 | -96.70 | -249.13 | -226.43 |
| Debt to Market Cap | 0.39 | 1.55 | 0.01 | 0.02 | 0.00 |
| Interest Debt Per Share | 0.22 | 0.59 | 0.05 | 0.07 | 0.09 |
| Net Debt to EBITDA | -0.53 | -0.15 | -0.04 | 0.17 | 0.47 |
| Profitability Margins | |||||
| Gross Profit Margin | -122400.15% | 10.83% | -1068.03% | -371.02% | -5.90% |
| EBIT Margin | -658713.11% | -38883.04% | -2435.85% | -886.13% | -1490.21% |
| EBITDA Margin | -617481.55% | -38378.53% | -2254.79% | -847.93% | -1418.71% |
| Operating Profit Margin | -602467.84% | -6253.93% | -2461.74% | -870.75% | -1455.13% |
| Pretax Profit Margin | -586840.24% | -38692.98% | -2461.31% | -889.62% | -1496.64% |
| Net Profit Margin | -553029.27% | -38513.04% | -1850.75% | -775.35% | -1288.84% |
| Continuous Operations Profit Margin | -411111.74% | -38692.98% | -2081.80% | -805.75% | -1288.84% |
| Net Income Per EBT | 94.24% | 99.53% | 75.19% | 87.16% | 86.12% |
| EBT Per EBIT | 97.41% | 618.70% | 99.98% | 102.17% | 102.85% |
| Return on Assets (ROA) | -278.92% | -705.50% | -16.44% | -31.68% | -21.72% |
| Return on Equity (ROE) | 81.33% | 809.96% | -17.52% | -33.93% | -22.60% |
| Return on Capital Employed (ROCE) | 92.12% | 310.89% | -23.16% | -37.19% | -25.21% |
| Return on Invested Capital (ROIC) | 128.84% | -326.00% | -19.42% | -33.46% | -21.61% |
| Return on Tangible Assets | -465.08% | -807.46% | 19.61% | 48.25% | 36.77% |
| Earnings Yield | -71.80% | -1001.63% | -37.65% | -157.05% | -17.56% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.14 | 0.04 | -275.75 | 6.01 | 11.55 |
| Payables Turnover | 0.23 | 0.02 | 2.02 | 4.81 | 0.71 |
| Inventory Turnover | 1.68 | 0.07 | 2.30 | 3.71 | 0.81 |
| Fixed Asset Turnover | 0.01 | 0.42 | 0.58 | 1.82 | 0.54 |
| Asset Turnover | 0.00 | 0.02 | 0.01 | 0.04 | 0.02 |
| Working Capital Turnover Ratio | -0.00 | -0.06 | 0.18 | 0.36 | 0.21 |
| Cash Conversion Cycle | 1258.11 | -404.32 | -23.43 | 83.25 | -29.39 |
| Days of Sales Outstanding | 2607.86 | 8886.40 | -1.32 | 60.76 | 31.60 |
| Days of Inventory Outstanding | 217.07 | 5398.66 | 158.57 | 98.44 | 450.79 |
| Days of Payables Outstanding | 1566.82 | 14689.37 | 180.68 | 75.95 | 511.79 |
| Operating Cycle | 2824.93 | 14285.05 | 157.25 | 159.20 | 482.39 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.43 | -0.39 | -0.72 | -1.17 | -1.30 |
| Free Cash Flow Per Share | -0.43 | -0.39 | -0.72 | -1.17 | -1.30 |
| Dividend Paid and CapEx Coverage Ratio | -1226713.50 | 0.00 | 0.00 | -2356806.00 | -2154148.50 |
| Capital Expenditure Coverage Ratio | -1226713.50 | 0.00 | 0.00 | -2356806.00 | -2154148.50 |
| Operating Cash Flow Coverage Ratio | -2.29 | -0.74 | -16.55 | -18.82 | -15.64 |
| Operating Cash Flow to Sales Ratio | -7479.96 | -46.22 | -24.07 | -6.12 | -12.99 |
| Free Cash Flow Yield | -97.12% | -120.20% | -48.98% | -123.94% | -17.70% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.38 | -0.10 | -2.66 | -0.64 | -5.69 |
| Price-to-Sales (P/S) Ratio | 7702.11 | 38.45 | 49.15 | 4.94 | 73.40 |
| Price-to-Book (P/B) Ratio | -1.13 | -0.81 | 0.47 | 0.22 | 1.29 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.03 | -0.83 | -2.04 | -0.81 | -5.65 |
| Price-to-Operating Cash Flow Ratio | -1.03 | -0.83 | -2.04 | -0.81 | -5.65 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | -0.00 | 0.04 | -0.04 | 0.52 |
| Enterprise Value Multiple | -1.77 | -0.25 | -2.22 | -0.41 | -4.70 |
| Enterprise Value | 7.19M | 9.01M | 15.09M | 5.36M | 44.27M |
| EV to EBITDA | -1.77 | -0.25 | -2.22 | -0.41 | -4.70 |
| EV to Sales | 10957.87 | 94.93 | 50.12 | 3.48 | 66.73 |
| EV to Free Cash Flow | -1.46 | -2.05 | -2.08 | -0.57 | -5.14 |
| EV to Operating Cash Flow | -1.46 | -2.05 | -2.08 | -0.57 | -5.14 |
| Tangible Book Value Per Share | -0.42 | -0.43 | -3.04 | -3.33 | -3.74 |
| Shareholders’ Equity Per Share | -0.39 | -0.40 | 3.16 | 4.38 | 5.70 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.30 | 0.03 | 0.15 | 0.09 | 0.14 |
| Revenue Per Share | 0.00 | 0.01 | 0.03 | 0.19 | 0.10 |
| Net Income Per Share | -0.32 | -3.22 | -0.55 | -1.49 | -1.29 |
| Tax Burden | 0.94 | 1.00 | 0.75 | 0.87 | 0.86 |
| Interest Burden | 0.89 | 1.00 | 1.01 | 1.00 | 1.00 |
| Research & Development to Revenue | 4061.89 | 29.60 | 4.44 | 0.91 | 3.14 |
| SG&A to Revenue | 738.78 | 14.08 | 10.17 | 3.95 | 6.77 |
| Stock-Based Compensation to Revenue | -1810.07 | 0.38 | 1.34 | 1.75 | 1.97 |
| Income Quality | 1.35 | 0.12 | 1.30 | 0.79 | 1.01 |
Currency in AUD

